<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药时代 | wechat-feeds</title><link>http://MzI5NzY0NDQyNQ.favicon.privacyhide.com/favicon.ico</link><description>欢迎您走进药时代！这是一个千载难逢的医药研发新时代！我们分享最新的有价值的行业资讯，讲述医药背后感人的故事，举办形式多样、内容丰富的线上线下活动，与朋友们一起学习成长，将新药研发事业进行到底，让新药带给世界更多更大的健康和希望！</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 24 Feb 2021 11:49:13 +0800</pubDate><image><url>http://MzI5NzY0NDQyNQ.favicon.privacyhide.com/favicon.ico</url><title>药时代 | wechat-feeds</title><link>http://MzI5NzY0NDQyNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>和黄苏慰国：中国创新药公司真正走向国际市场要拿得出过硬的产品</title><link>https://mp.weixin.qq.com/s/FVlmRQdel7O8c6rSIiDkgQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbC6poWEok0edMYV7m8MOib4PDLPSDUGTN5iaWtD4pRfogGM7EYeuNLnvtg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>泽璟盛泽林：License-in模式下未来盈利能力需与分成费用平衡</title><link>https://mp.weixin.qq.com/s/yGvBQwryk-udzFApM7C4PQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbCaXVnXQWRbCFtB83xiaWQxnRSKvGaBavSWRTdI0WBz3ZaWY52KWb78Nw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>德琪医药ATG-010（Selinexor）新药上市申请获国家药品监督管理局优先审评</title><link>https://mp.weixin.qq.com/s/QbwShxB38-GGjmSfMH8NOA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbCVKqfZ1Wh9wXwFux0TLcZ2dLT3YWUY7cOEQKgmBcqd3Dd5Iuq0DAFVg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>热烈祝贺德琪医药！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>三叶草生物完成2.3亿美元C轮融资并获超额募集</title><link>https://mp.weixin.qq.com/s/GaP1tmlzxbAfeIETbxrMiQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbC7icqbJTRkeuEqdFmicla63uesq0fdAlmqmaYzusCc4tpzyiaxql5Z3m2A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>完成C轮融资后，三叶草生物在过去12个月的总融资额超过4亿美元（约25亿人民币）。]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>深度洞察 | 2021年CAR-T行业研究报告</title><link>https://mp.weixin.qq.com/s/36FwC4MX5MeUGlxK2C85fA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbCfakhP4eSaaCvP5xW4Jt47HnDYfkW68qGfvTXicxNy6ICFL1eTgG2ywg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>癌症疫苗突破：个性化新抗原，实现四年强效持久抗癌</title><link>https://mp.weixin.qq.com/s/dmJ3_UUfA-AiFgu_gEXKDg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbCCJ5mbOeo4BHP5Sa4k2QaNCfJdZ5suN9XdqfhHtnJoFQJM5L3jdh9SQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>盐皮质激素拮抗剂异军突起，国内糖尿病领域还有哪些新药值得关注？</title><link>https://mp.weixin.qq.com/s/ulLXx7bwe5c-Vz8SpvNSqA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9WfJmiam9qPI7Uo2vyhevnbCd4iaQ7Fia3BMuM7eiaLppRgfTpEHic5fQo11a0766W94D0vYFTBAjTI38g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>高瓴创投领投了2家张江企业！祝贺康沣生物和微密医疗！</title><link>https://mp.weixin.qq.com/s/QBFwmSiBj4abtg7pxYUzzg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/tuhn9vZSzW7VWJl8Fqxv7vC7yOoR5F2tiaZ0gCxv3Q2aDs9ZQiaNH6wAM0rzmtJf6TFs7AZjpW4SAaQicUPIFDoTw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:00:20 +0800</pubDate></item><item><title>信达刘勇军：新药临床转化效率与策略决定其上市进度与商业价值</title><link>https://mp.weixin.qq.com/s/TxW73NmOEPYuHjYv8RaTHQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPEDJLxAMU5q9VfctXo1On0R6eLF8qDicbgRMQyKeKVibk3TwQAcYnEibWGaw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>药明直播间 | 生物制药系列(七)：基于质谱的生物药结构表征策略与案例分享</title><link>https://mp.weixin.qq.com/s/x8cmiLkVSiLbWRWkYzLNRg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPED5HI92yBaWOibibK8t97NziaKuFjwOI2XzjlMzxwiahKvDl7ZFGFMGAbNdA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>2月25日下午3点，药明生物分析科学部高级主任，黄晋萃博士将做客药明直播间，与大家分享基于质谱进行生物药结构表征策略，并结合案例分享技术经验。]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>泽生周明东：药物创新真正“卡脖子”的是思想与资本的局限</title><link>https://mp.weixin.qq.com/s/9CdfcpAL0YvLdPrjqnvDFw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPEDZiaut9n4ukmWuDo2nFPzexUibk0sibuq6GBDsTAXLDgtDJFTS5Vh3A0Ew/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>创新靶点深度探析，助您2021更“牛”气</title><link>https://mp.weixin.qq.com/s/qtmjq9R1sQ7OiwVDJlxj3g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPEDtwYjV3yH7cu2JfkgEmlNzpaJqUBXGHFSkA1I8jBbkYy85Dme8R974A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>关注药时代，共创新未来！]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>一文初识：命运多舛的马兜铃酸！</title><link>https://mp.weixin.qq.com/s/tY7BrXMhBbUChw_cU9Lncw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPEDaTD4NiaICGmKo2fC4J4qYEIs0NGUicTnHZ0v5Rb1KLaVKibBzcfN442iaA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>关注药时代，共创新未来！]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>全球创新疗法系列（一）：基因治疗技术进展</title><link>https://mp.weixin.qq.com/s/nHGtyE-uKLQQfUNuYQSNUw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPEDZCoB6f720uibyKRv8Bnpo8tLZibZjqAzQxyVic5hbibHT2lzIJZ5qm5sBQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>关注药时代，共创新未来！]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>重磅！世界首例自分泌PD-1抗体CAR-T细胞联合疗法治疗复发实体瘤临床报告！CAR-T白泽剑，剑指实体瘤！</title><link>https://mp.weixin.qq.com/s/rNXjwtLUJjDyVIwey7lKEg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Yjn27zvp1KSicVH6eceu9KKyeiaYUyOUFlMHtfLzdp5tMO4ib15Oekk6mJVH9poVccw0zIWNyK3MRhnB3icq5b2VVQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>大话AI | 药物研发中人工智能的发展思考与未来展望（一）</title><link>https://mp.weixin.qq.com/s/C7qvtKSk85_L8P9nBoiL_A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9U6vlgUtOlxAvzBqh8ojPEDnOPrY9HMmQ6ibxuNicx1ndjZb9NhrukUPYgC1J9Wz0HywsACLAhcrK6Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药时代密切关注AI在新药研发中的应用]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:38:21 +0800</pubDate></item><item><title>何如意：license in产品该如何实现快速上市？药企出海临床试验设计该怎么做？一个最佳的临床是怎样的？</title><link>https://mp.weixin.qq.com/s/a-yf6g0PgYQSfAfIthGs4A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9XuBGIq675jiaSHu3qyAB9ibHwYw7MY4mgYRJBveR3lNyq1kib6Dbp1PVlBYrChrgmSibob5paEl3tNhw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:10:20 +0800</pubDate></item><item><title>陪跑11年回报近百倍，Moderna投资人为什么能成功？中美医药投资有哪些差异？详解美国四类投资模式</title><link>https://mp.weixin.qq.com/s/BkRDeCeDf3OwQdghLss2VA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9XuBGIq675jiaSHu3qyAB9ibHkx6VkzlibZsH9eAlBiafA5wx4L1dFszWJBDwknoicIo6suDMiafsGOicX6A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>走进药时代，共创新未来！]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:10:20 +0800</pubDate></item><item><title>博腾药时代直播第八期 | 如何高效开展CDMO项目中试放大?</title><link>https://mp.weixin.qq.com/s/dF1YmwgPTlrGn1uVIezRFw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9XuBGIq675jiaSHu3qyAB9ibHQI2MibxUglcuQFZicJGia5qKFVuLMxlibyaiaDTZ8IgMa1wiaVmibe5cUB7MA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>热烈欢迎朋友们观看！还有很棒的礼品等着您！~]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:10:20 +0800</pubDate></item><item><title>鏖战目录！如何规划医保、基药、集采、临床指南等市场准入目录优先级？</title><link>https://mp.weixin.qq.com/s/CGdmGe2d0uobMU3mGSfxAw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/Lkw2iaE07M9XuBGIq675jiaSHu3qyAB9ibHdICPFTJ0gUPuO8UbdaC1qSFjKWyVJFBDy7esdYe6AAyZCCrC3aeVSA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>关于药时代，与十多万专业朋友们同频、同台、同在！]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:10:20 +0800</pubDate></item></channel></rss>